Viviana Cortiana,Harshitha Vallabhaneni,Jenna Ghazal et al.
Viviana Cortiana et al.
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification sys...
Large intramuscular hematoma due to acquired Factor VIII inhibitors in post Polycythemia Vera-Myelofibrosis [0.03%]
因获得性八因子抑制物导致的大腿肌肉内血肿（曾患多毛细胞白血病-骨髓纤维化）
Raghuveer S Prabhu,Sarath R V S,Rahmathullah S N
Raghuveer S Prabhu
A 59-year-old man with Janus kinase-2 (JAK2) V617F mutation-positive polycythemia vera, evolving to myelofibrosis presented with a right thigh hematoma. Further evaluation showed prolonged activated partial thromboplastin time (aPTT), which...
The short-term Cardiotoxicity after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective single center experience [0.03%]
同种异基因造血干细胞移植后的心脏毒性：单中心回顾性分析体验
Jean El Cheikh,Ibrahim Hasan,Mustafa Saleh et al.
Jean El Cheikh et al.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the best cure for many hematologic diseases, but it is associated with multiple short and long term cardiovascular adverse effects. This retrospective study assess...
Moving the Needle in KMT2A Rearranged Pediatric B-Cell Acute Lymphoblastic Leukemia: Newer agents and novel approaches [0.03%]
儿童B细胞急性淋巴细胞白血病KMT2A重排的治疗进展：新药和创新疗法
Anwesha Ray,Aditi Jain,Mona Vijayaran et al.
Anwesha Ray et al.
Pediatric B-cell acute lymphoblastic leukemia (B-ALL) has been the poster child of progressive success in the development of leukemia therapy. Among the genomically defined high-risk subtypes of B-ALL are those with KMT2A-rearrangement (r) ...
Clinical Characteristics and Treatment Outcomes of Acute Myeloid Leukemia in Adolescent and Young Adult versus Adult Patients: A Single-Center Experience in Qatar [0.03%]
卡塔尔单中心年轻成人急性髓系白血病患者与成人患者的临床特征及治疗结局的比较研究
Shehab Fareed,Abdulrahman Fadhl Al-Mashdali,Hawraa Shwaylia et al.
Shehab Fareed et al.
Acute myeloid leukemia (AML) presents differently across age groups, with unique challenges in the adolescent and young adult (AYA) populations. This study compares clinical characteristics and outcomes between AYA and adult AML patients in...
Genetic and Clinical Progression of MYSM1 Related Bone Marrow Failure into Myeloid Malignancies: Case Series and Review of Literature [0.03%]
MYSM1相关骨髓衰竭向髓系恶性肿瘤进展的遗传和临床特点：病例系列及文献回顾
Alfadil Haroon,Syed Osman Ahmed,Chokri Ben Lamine et al.
Alfadil Haroon et al.
MYSM1, located on chromosome 1p32.1, encodes histone H2A deubiquitinase, a transcription regulator involved in DNA damage response. Biallelic MYSM1 variants are linked to rare bone marrow failure syndromes, presenting with cytopenia, B-cell...
Impact of Anemia Management on Bleeding Outcomes in Anticoagulated Patients: A Retrospective Cohort Analysis [0.03%]
抗凝患者的贫血管理对出血结局的影响：回顾性队列分析
Shea-Lee Godin,Christopher Hanna,Edgar Naut et al.
Shea-Lee Godin et al.
Anticoagulation therapy is essential to manage thromboembolic conditions such as atrial fibrillation and venous thromboembolism. While effective, it carries significant bleeding risks, with annual rates ranging from 10-17% for all events an...
Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region [0.03%]
复发/难治性多发性骨髓瘤：海湾国家患者的标准治疗护理标准
Ahmad Alhuraiji,Khalil Al Farsi,Kayane Mheidly et al.
Ahmad Alhuraiji et al.
Clinical management of patients with relapsed/refractory multiple myeloma (RRMM) can be challenging, whereby each relapse is associated with progressively poorer outcomes. In addition, changes in disease biology and patient characteristics ...
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group [0.03%]
浆细胞瘤工作组关于新诊断多发性骨髓瘤达雷妥尤单抗基四药方案治疗的临床实践专家共识及推荐意见
Wenming Chen,Zhen Cai,James Cs Chim et al.
Wenming Chen et al.
The therapeutic outcomes of clinical trials for incorporating anti-CD38 monoclonal antibodies (including isatuximab and daratumumab) into the bortezomib/lenalidomide/dexamethasone (VRd) triplet therapy backbone as the first-line treatment f...
Robin Noel,Aude Charbonnier,Bérénice Schell et al.
Robin Noel et al.